Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) EBT Margin (2019 - 2025)

Pulmonx (LUNG) has disclosed EBT Margin for 7 consecutive years, with 64.31% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 412.0% to 64.31% in Q3 2025 year-over-year; TTM through Sep 2025 was 61.39%, a 972.0% increase, with the full-year FY2024 number at 66.71%, up 2106.0% from a year prior.
  • EBT Margin was 64.31% for Q3 2025 at Pulmonx, down from 62.85% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 55.28% in Q4 2024 to a low of 146.14% in Q1 2022.
  • A 5-year average of 88.06% and a median of 84.0% in 2023 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 21720bps in 2021; the steepest drop was -5252bps in 2021.
  • Pulmonx's EBT Margin stood at 93.77% in 2021, then rose by 3bps to 91.0% in 2022, then increased by 22bps to 70.75% in 2023, then increased by 22bps to 55.28% in 2024, then decreased by -16bps to 64.31% in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBT Margin are 64.31% (Q3 2025), 62.85% (Q2 2025), and 63.51% (Q1 2025).